"Real-world" eligibility for aducanumab depends on clinical setting and patients' journey.
Alessandro PadovaniSalvatore CaratozzoloLuca RozziniAndrea PilottoAlberto BenussiGioacchino TedeschiPublished in: Journal of the American Geriatrics Society (2021)